Loading grant details…
Completed
RESEARCH
Europe PMC
Dapagliflozin for treating chronic kidney disease (ID3866)
£656.3K
GBP
| Funder | National Institute for Health Research |
|---|---|
| Recipient Organization | The University of Sheffield |
| Country | United Kingdom |
| Start Date | Apr 29, 2021 |
| End Date | Oct 14, 2021 |
| Duration | 168 days |
| Number of Grantees | 1 |
| Roles | Award Holder |
| Data Source | Europe PMC |
| Grant ID | NIHR134422 |
Grant Description
To appraise the clinical and cost effectiveness of dapagliflozin within its marketing authorisation for treating chronic kidney disease.
All Grantees
The University of Sheffield
Advertisement
Advertisement
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Start Year
2021
End Year
2021
Grantees
1
Related Grants
Lassa Fever Vaccine Efficacy And Prevention for West Africa...
European & Developing Countries Clinical...
€2.29M EUR
Platform Adaptive trial of NOvel antiviRals for eArly treatM...
National Institute for Health and Care R...
£2.14M GBP
The Swedish contribution to the construction and operation o...
Swedish Research Council
1.95M kr SEK
Advertisement
